Prostate cancer is the most common cancer occurring in American men of all races.
It is also the second leading cause of cancer death among men in the USA. Bone metastasis is a frequent occurrence in men with advanced prostate cancer, with skeletal-related events being a common complication and having negative consequences, leading to severe pain, increased health care costs, increased risk of death, and decreased quality of life for patients. Bone loss can also result from antiandrogen therapy, which can further contribute to skeletal-related events. Treatment with antiresorptive agents bisphosphonates, and the newly approved denosumab, a receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor, has been shown to reduce the risk of skeletal-related complications and prevent treatment-induced bone loss in patients with advanced prostate cancer. This review discusses the role of antiresorptive agents bisphosphonates and RANK-L inhibitor in the current treatment of advanced prostate cancer by examining the primary literature and also focuses on the likely role of the bisphosphonates in the treatment of advanced prostate cancer in the future.
Written by:
Iranikhah M, Stricker S, Freeman MK. Are you the author?
Samford University, McWhorter School of Pharmacy, Birmingham, AL, USA.
Reference: Cancer Manag Res. 2014 May 3;6:217-24.
doi: 10.2147/CMAR.S40151
PubMed Abstract
PMID: 24833918
UroToday.com Bone Metastases Section
